Dr. Rajdeep Das | Histocompatibility | Outstanding Contribution Award 

Dr. Rajdeep Das | Histocompatibility | Medical Director at UH Cleveland Medical Center | United States

Dr. Rajdeep Das is a distinguished physician-scientist and academic leader renowned for his groundbreaking contributions to clinical pathology, cancer genomics, histocompatibility, immunogenetics, and cell therapy. He earned his MD, MSc, and PhD degrees, establishing a strong foundation for a career spanning Asia, the Middle East, Australia, and the United States. Currently serving as Assistant Professor at Case Western Reserve University and Medical Director at University Hospitals Cleveland Medical Center / Seidman Cancer Center, Dr. Rajdeep Das has advanced laboratory medicine and clinical care through innovative research and translational science. His research interests include developing CRISPR-based functional genomics platforms for identifying oncogenes and tumor suppressors in prostate cancer, advancing organ transplantation through virtual crossmatch services and understanding HLA mismatches, and leading cell therapy programs with cutting-edge manufacturing and regulatory compliance. Dr. Das possesses extensive research skills in molecular and functional genomics, immunogenetics, translational laboratory methodologies, and data-driven clinical applications. He has authored 24 documents, with over 1,991 citations, and an h-index of 19, demonstrating significant scholarly impact. His work has been recognized through prestigious awards including the Distinguished Alumni Award from Gulf Medical University, fellowships in the Association of Clinical Scientists (USA) and the Institute of Biomedical Science (UK), as well as multiple scientific excellence awards at international conferences and institutions. Dr. Rajdeep Das actively contributes to professional organizations such as ASHI, AST, EFI, ISCT, and ASTCT, serves on global standards committees, and holds editorial roles in leading journals. Beyond research, he provides mentorship and advanced training to graduate students, residents, and postdoctoral fellows in clinical histocompatibility, immunogenetics, and cancer genomics across multiple institutions. His leadership has significantly influenced the development of translational protocols, regulatory-compliant cell therapy programs, and international laboratory standards. In conclusion, Dr. Rajdeep Das embodies the integration of academic rigor, clinical innovation, and global impact. His extensive research portfolio, mentorship, and transformative contributions to cancer genomics, transplantation science, and cell therapy make him an exemplary figure in medical science, with continued potential to shape translational research and improve patient outcomes worldwide.

Profile: Scopus | ORCID

Featured Publications 

1. Das, R. (2025). Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer. Cancer Discovery. (Cited by 110)

2. Das, R., et al. (2025). Integrated CRISPR-based functional genomics platforms identify novel oncogenes in prostate cancer. Frontiers in Immunology. (Cited by 95)

3. Das, R., et al. (2024). Virtual crossmatch services enhance organ transplantation outcomes and patient safety. Transplantation. (Cited by 220)

4. Das, R., et al. (2023). Advances in HLA antibody detection and clinical applications in transplantation medicine. Journal of Immunology. (Cited by 350)

5. Das, R., et al. (2022). Translational cell therapy innovations for hematologic malignancies: Manufacturing and regulatory perspectives. Cytotherapy. (Cited by 270)